Developing biotherapeutics and novel modalities for treating oncology indications still have key challenges, such as determining the first-in-human (FIH) starting dose. In this webinar, Piet van der Graaf, Head of QSP at Certara discusses bispecific antibodies and opportunities for clinical pharmacology and QSP, current industry best practices, and successful case studies with our partners.
Quantitative Systems Pharmacology (QSP) consulting services at Certara combine computational modeling and experimental data to address complex challenges in drug development. QSP bridges the gap between biology and pharmacology by generating a quantitative math model to characterize therapeutic pharmacology in the context of a complex biological system, disease processes, and therapeutic mechanism of action (MOA). By examining interactions between drugs, biological systems, and diseases, QSP offers a robust framework for predicting clinical outcomes, optimizing therapeutic strategies, and streamlining decision-making. Certara’s regulatory-ready platforms support reproducible model development across various therapeutic areas, including oncology, inflammation and immunology, and neurodegenerative diseases.
